Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC2 | Q92887 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690166 | 0.91 | ABCC2 (0.50) | ABCC2 | |
| SCHEMBL2690163 | 0.91 | ABCC2 (0.50) | ABCC2 | |
| SCHEMBL2690165 | 0.91 | ABCC2 (0.50) | ABCC2 | |
| SCHEMBL2691817 | 0.90 | ABCC2 (0.49) | ABCC2 | |
| SCHEMBL2691823 | 0.90 | ABCC2 (0.49) | ABCC2 | |
| SCHEMBL3280848 | 0.90 | ABCC2 (0.55) | ABCC2 | |
| SCHEMBL4119711 | 0.88 | ABCC2 (0.48) | ABCC2 | |
| SCHEMBL4129896 | 0.87 | ABCC2 (0.47) | ABCC2 | |
| SCHEMBL15122304 | 0.83 | ABCC2 (0.60) | ABCC2 | |
| SCHEMBL3106852 | 0.83 | ABCC2 (0.59) | ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253671-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | claimed |
| EP-1861396-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006092608-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | claimed |
| US-20090253671-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| EP-1861396-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006092608-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253671-A1 | TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY | AZI2, AAAS, QDPR | ABCC2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.